Pembrolizumab +/- SD-101 in Hormone-Naïve Oligometastatic Prostate Cancer With RT and iADT
University of California, San Francisco
University of California, San Francisco
BioXcel Therapeutics Inc
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
University of California, San Francisco
Eli Lilly and Company
Advaxis, Inc.
University of Wisconsin, Madison
Xencor, Inc.
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Gary Onik MD